71 results about "Cholesterol total" patented technology

The invention provides an Auricularia auricula polysaccharide, its application and preparation method thereof, which belong to the technical field of improving polysaccharide. After being degreased, the Auricularia auricula is subjected to preliminary enzymolysis under the effect of helicase, is further subjected to deep enzymolysis under the effect of complex enzyme through synergetic ultrasound-assisted degradation and extraction with H2O2, and is subjected to mixed fermentation by Lactobacillus bulgaricus, Streptococcus thermophilus and Bifidobacterium longum, the obtained fermented Auricularia auricula polysaccharide is subjected to a phosphorylation reaction under the effect of a phosphorylation reagent, and after further deproteinization and decolorization, the obtained fermented Auricularia auricula polysaccharide is chelated with zinc salt to obtain a polysaccharide-zinc compound, and the amount of the extracted Auricularia auricula polysaccharide is improved. The finished product of the invention has the effects of reducing blood sugar and blood fat, regulating total cholesterol and effectively improving HDL cholesterol.

The invention provides a method for preparing quintuple diglyceride oil for improving blood vessel health through enzymolysis, application and a product, and belongs to the technical field of enzyme engineering. The preparation method comprises the following steps: mixing low-erucic acid rapeseed oil, glycerol, water, fatty acid and lipase, and carrying out enzymolysis reaction, molecular distillation, decoloration and deodorization to obtain diglyceride oil; the lipase is a mixture of Candida antarctica Aspergillus niger lipase, Candida column lipase and bovine pancreas lipase, and the weight ratio of the low-erucic acid rapeseed oil to the glycerin to the water to the fatty acid to the lipase is 500: (80-100): (1-2): (30-60): (10-20). The diglyceride oil prepared by the method can be used for preparing a diglyceride oil composition, and has five functions of reducing blood uric acid, reducing blood total cholesterol, reducing blood triglyceride, reducing blood sugar and increasing blood flow velocity to improve blood vessel health.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The invention belongs to the technical field of natural medicines, and particularly discloses a lipase inhibitor with a specific structure as well as a preparation method and application thereof, the inhibitor is derived from grape leaves and contains C6-C3-C6, 1, 2-benzopyrone, diphenyl ethylene and a phenolic hydroxyl structure, and the lipase inhibitor is a lipase inhibitor with a specific structure. Comprising the following components in percentage by mass: 72.1 to 97.5 percent of flavonoids, 2.5 to 5.1 percent of coumarins, 2.0 to 3.2 percent of stilbenes and 5.1 to 8.3 percent of phenolic acids. According to the lipase inhibitor with the specific structure as well as the preparation method and the application of the lipase inhibitor, the inhibitor can inhibit secretion of lipase, prevent fat from being decomposed into absorbable free fatty acid and monoacylglycerol, and reduce fat absorption; the total cholesterol and the low-density lipoprotein cholesterol are reduced, the blood fat level is improved, and the composition can be applied to preparation of health-care products, functional foods, sports nutritious foods and formula foods for special medical purposes.

The invention relates to N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid or a pharmaceutical composition and application thereof, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the N-fluorenylmethoxycarbonyl-L-2-amino-5-phenylpentanoic acid is found to have the effects of reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol in serum and increasing high-density lipoprotein cholesterol in serum for the first time; the compound can be used for preparing a medicine for reducing total cholesterol in serum, a medicine for reducing triglyceride in serum, a medicine for reducing low-density lipoprotein cholesterol in serum and a medicine for increasing high-density lipoprotein cholesterol in serum, and can be used for preparing medicines for reducing total cholesterol in serum, triglyceride in serum, low-density lipoprotein cholesterol in serum and high-density lipoprotein cholesterol in serum. And an effective new means and a new way are provided for preparing the medicine for preventing or treating the hyperlipemia.

The invention relates to the technical field of biological medicine, in particular to application of cyclic dipeptide to improvement or treatment of dyslipidemia related diseases. According to the present invention, the research results show that the cyclo (glycerol-casein) dipeptide has good safety and cholesterol lowering activity, and can reduce mouse serum total cholesterol, low density lipoprotein cholesterol, increase serum high density lipoprotein cholesterol, reduce the content of liver total cholesterol, reduce liver fat accumulation, and slow down the weight increase of mice. The cyclic (glycerol-casein) dipeptide can realize the effect of lowering cholesterol by regulating intestinal flora. The cyclic (glycerol-tyrosine) dipeptide is derived from probiotics, food and medicines, belongs to food-borne cyclic dipeptide, and is high in safety and small in toxic and side effects. The cyclo (glycerol-casein) dipeptide is expected to be developed into a class of innovative medicines and health-care foods with the effect of reducing cholesterol, and has a very good application prospect. The invention also provides the cyclic (sweet-tyrosine) dipeptide and a health food and a pharmaceutical composition containing the cyclic (sweet-tyrosine) dipeptide.

The application provides a diglyceride oil containing alpha-linolenic acid for improving vascular health in six aspects and a preparation method and application, and relates to the technical field of enzyme engineering. The preparation method comprises the following steps: mixing oil, glycerol and water, and then adding a lipase Lecitase Ultra to obtain a pretreated mixture after stirring; the mixed oil is a mixture of safflower seed oil, yuanbao maple seed oil, perilla seed oil, milk thistle seed oil and peony seed oil; a lipase Lipase DFA Amano 15 and a lipase Palatase 20000L are pretreated to obtain a fixed mixed lipase, which is mixed with the pretreated mixture for enzymolysis, and then subjected to molecular distillation. Through the specific ratio of edible oil and the specific enzymolysis process, the product not only improves the stability and taste, but also improves the vascular health in multiple aspects of reducing blood uric acid, reducing total blood cholesterol, reducing blood triglyceride, reducing blood sugar, reducing blood pressure, resisting inflammation, resisting oxidation and preventing arterial thrombosis.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

According to the invention, the expression of GREB1 is knocked down in PVN of CD mice, the body weight and the one-week food intake of the mice are obviously improved, multiple biological indexes in plasma are obviously increased, the liver volume is obviously increased compared with a control group, the liver weight / body weight ratio is also obviously increased, lipid droplet deposition in the liver is obviously increased, and the expression level of adipogenic differentiation related proteins is obviously increased; the above prompts that after the expression of the GREB1 is knocked down by the PVN of the CD mouse, the NAFLD animal model can be obtained. The invention also discloses that after GREB1 is over-expressed by PVN of a mouse, the weight rise, total cholesterol and low-density lipoprotein increased in serum, increased liver volume and increased lipid droplet deposition in the liver of the mouse due to NAFLD diet induction can be improved. The above all prompt that the GREB1 agonist can prevent or treat the NAFLD disease.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

The application belongs to the technical field of traditional Chinese medicine exosomes, and particularly relates to mulberry-derived extracellular vesicle particles, a preparation method thereof and application thereof in the preparation of medicines for preventing and treating hyperlipidemia and related symptoms. The mulberry-derived extracellular vesicle particles provided by the application are prepared by using mulberries as raw materials, centrifuging the mulberries at different centrifugal speeds after juice extraction, and then performing density gradient centrifugation with a sucrose solution with a specific density. Experimental research shows that the mulberry-derived extracellular vesicle particles can significantly reduce total cholesterol, triglyceride and low-density lipoprotein in blood, inhibit the formation of aortic plaques caused by hyperlipidemia and lipid deposition in the liver, and are safe and non-toxic, and therefore can be used for the preparation of medicines for preventing and treating hyperlipidemia and related symptoms.

The application discloses a composition for improving blood lipid metabolism, which comprises the following raw materials: sweet cinnamon powder, rhodiola powder, roxburgh rose powder and curcuma zedoaria powder. The preparation method of the composition for improving blood lipid metabolism comprises the following steps: screening the sweet cinnamon powder, the rhodiola powder, the roxburgh rose powder and the curcuma zedoaria powder respectively, mixing them uniformly to obtain mixed powder; adding sterile deionized water into the mixed powder to obtain a mixed solution; adding a complex enzyme into the mixed solution for enzymolysis; after the enzymolysis is completed, the enzyme is inactivated, filtration is conducted, and the filtrate is freeze-dried to obtain the composition for improving blood lipid metabolism. The plant powder is subjected to mixed enzymolysis through multiple enzymes, the natural active substances in the plant powder are enriched, and the types of the enzymolysis products are enriched, so that the total cholesterol, the triglyceride and the low-density lipoprotein content in blood can be reduced, and the high-density lipoprotein content in blood can be increased.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.

The invention discloses a preparation method and application of cannabis sativa peptide with effects of reducing blood fat and adjusting lipid metabolism, belongs to the technical field of biology, and has a wide application prospect. The fructus cannabis peptide obtained by the technical scheme and the preparation method disclosed by the invention has the following effects: 1, the fructus cannabis peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving pancreatic lipase activity (the highest inhibition rate can reach 65.0%), so that digestion and absorption of a human body on lipid substances such as animal and vegetable oil and cholesterol are blocked; 2, the cannabis sativa peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving the abnormality of four items of blood fat, reducing the level of total cholesterol, triglyceride and low-density lipoprotein and remarkably improving the level of high-density lipoprotein; 3, the prepared cannabis sativa peptide can obviously relieve non-alcoholic fatty liver disease caused by obesity and reduce liver fat accumulation; 4, the cannabis sativa peptide prepared by the invention can effectively relieve the occurrence and progress of obesity, reduce the weight change rate and reduce the obesity index, and has good lipid-lowering and weight-losing effects.

1. The name of the design product: tester. 2. The use of the design product: the product is used with the matching test paper for the detection of blood sugar, uric acid, blood ketone, total cholesterol and triglyceride. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention discloses an achilles tendon rupture risk assessment system, and belongs to the technical field of data processing systems. The achilles tendon rupture risk assessment system comprises a calculation unit and a result output unit which are sequentially connected on a data main path. A computer program is stored in the calculation unit; when the computer program is executed by the processor, a pi value calculation method is operated; the pi value is calculated according to the following formula I: # imgabs0 #, wherein e is a natural constant, and X1 is a dimensionless value of the height of the subject with cm as a dimension; x2 is a dimensionless value of the content of triglyceride with mmol / L as a dimension in the blood of the subject; x3 is a dimensionless value of the age of the subject with the age as the dimension; x4 is a dimensionless value of diastolic pressure of the subject in mmHg dimension; x5 is a dimensionless value of the content of fasting blood glucose with mmol / L as a dimension in the blood of the subject; x6 is the dimensionless value of the total cholesterol content of the blood of the subject with mmol / L as the dimension; x7 is a dimensionless numerical value of the body mass index of the subject with kg / m < 2 > as a dimension. The system and the method provided by the invention are comprehensive, effective and accurate in evaluation.

A phloretin derivative and its use in the medicine for treating diabetes-associated non-alcoholic fatty liver, which relates to the technical field of medicine, in particular to the compound shown in formula (1) and its activity of alleviating diabetes metabolic syndrome-related non-alcoholic fatty liver; the pharmacological experimental results show that the compound shown in formula (1) can significantly alleviate hepatomegaly, reduce the presence of lipid droplets in liver tissues, restore the morphology of liver cells, and reduce the contents of total cholesterol, triglyceride and low-density lipoprotein in the blood, reduce related inflammatory indexes, and enhance antioxidant activity.

The invention provides pediococcus acidilactici XZFMCC101.23156, a microbial preparation, an antibacterial composition and application of the pediococcus acidilactici XZFMCC101.23156, and belongs to the technical field of functional microorganisms. The preservation number of the pediococcus acidilactici XZFMCC101.23156 is GDMCC No: 66860, and the pediococcus acidilactici XZFMCC101.23156 can be used as a functional microbial agent to be applied in vivo to improve diseases such as hyperlipidemia and the like, and can also achieve the effect of reducing body weight. The result of the embodiment shows that the culture supernatant of the pediococcus acidilactici XZFMCC101.23156 can effectively reduce the total cholesterol, the triglyceride, the low-density lipoprotein and the high-density lipoprotein in a rat body. The pediococcus acidilactici XZFMCC101.23156 provides a new way for the development of oral probiotic preparations and the preparation of foods, drinks, health care products and medicines with the function of degrading cholesterol.

1. Name of the design product: multifunctional measuring instrument (YTN21). 2. Use of the design product: for measuring blood pressure, blood sugar, uric acid and total cholesterol for users. 3. Design points of the design product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The application discloses a kind of traditional Chinese medicine preparation for treating hyperlipidemia, which is prepared from the following raw medicinal materials: radix codonopsis 10-20 g, astragalus 25-35 g, gynostemma pentaphyllum 10-20 g, atractylodes 10-20 g, zanthoxylum 3-8 g, monascus 10-15 g, and galangal 10-20 g. When treating, it is orally taken, one dose per day, taken twice, taken half an hour after breakfast and dinner, and continuously taken for 4 weeks as a treatment course. The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages that it is helpful to improve hyperlipidemia, and the serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and other indicators of patients after treatment are obviously better than those of the control group (oral atorvastatin), with statistical significance (P<0.05). The traditional Chinese medicine preparation for treating hyperlipidemia has the advantages of remarkable curative effect, good safety, low price and simple prescription, and has high clinical popularization value.

The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

The invention relates to the technical field of biological medicines, and particularly discloses application of mebendazole in preparation of a medicine for treating metabolism-related fatty liver diseases. Mebendazole has a remarkable blood fat reducing effect and can remarkably reduce the level of total cholesterol and / or triglyceride and / or low-density lipoprotein in serum; the weight can be reduced, the fatty liver can be improved, and wide application prospects are achieved for obese people. The medicine is simple and convenient to take and easy to absorb by oral administration. In addition, mebendazole is easy to obtain, and compared with other imported drugs, the mebendazole is low in price, high in cost performance, easy to accept by patients and convenient to transport and store.

The invention discloses a polysaccharide composition for treating chronic alcoholic liver injury and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is prepared by crushing phellinus linteus linteus, bolete, morchella and cordyceps militaris, mixing the crushed materials according to a mass ratio of 4: 2: 2: 2, performing water ultrasonic extraction, and performing hot water extraction. The polysaccharide composition can reduce fat vacuolation and hepatocyte swelling in the liver, inhibit expression of liver function related enzymes such as ALT and AST, improve secretion of blood fat such as total cholesterol, triglyceride and high-density lipoprotein cholesterol and reduce expression of inflammatory factors such as IL-1beta and TNF-alpha in the liver, and the effect of the polysaccharide composition is better than that of single polysaccharide. The polysaccharide composition can relieve liver injury caused by long-term drinking and achieve the effects of dispelling the effects of alcohol and protecting the liver.

The invention discloses a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, and relates to the technical field of pharmacy, in particular to a traditional Chinese medicine formula for preventing and treating body artery and blood vessel diseases, the traditional Chinese medicine composition is prepared from the following raw material medicines: 100g of radix puerariae, 100g of herba epimedii, 100g of herba leonuri, 50g of dioscorea panthaica, 50g of raw endothelium corneum gigeriae galli, 50g of fructus aurantii immaturus, 50g of rhizoma dioscoreae nipponicae, 50g of lumbricus and 50g of kapok leaves. Pharmacodynamic tests prove that compared with related traditional Chinese medicine prescriptions in the prior art, the traditional Chinese medicine composition can significantly reduce the intima-media thickness of blood vessels, reduce the area proportion of plaques, improve the blood vessel stenosis rate, and improve the curative effect. 0.05 in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride and low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol), protecting vascular endothelial function (increasing the content of vascular endothelial relaxation factor NO and reducing endothelin ET level) and the like, and the pharmaceutical composition is superior to the prior art group (Plt: 0.05) in terms of prolonging thrombosis time, increasing microcirculation blood flow velocity, regulating blood lipid level (reducing total cholesterol, triglyceride, low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol).